Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 3.24%6.05B | 4.30%3.92B | -13.06%1.77B | -0.53%9.25B | -8.03%5.86B | -8.92%3.76B | 7.06%2.04B | -0.82%9.3B | -4.14%6.37B | 0.75%4.12B |
| Operating income | 3.24%6.05B | 4.30%3.92B | -13.06%1.77B | -0.53%9.25B | -8.03%5.86B | -8.92%3.76B | 7.06%2.04B | -0.82%9.3B | -4.14%6.37B | 0.75%4.12B |
| Operating expenses | -7.38%-3.84B | -6.68%-2.47B | 16.28%-1.1B | -6.30%-6.32B | 5.67%-3.57B | 6.65%-2.32B | -14.26%-1.31B | 6.36%-5.95B | 7.43%-3.79B | 0.82%-2.48B |
| Gross profit | -3.23%2.21B | 0.49%1.45B | -7.23%671.62M | -12.69%2.92B | -11.48%2.29B | -12.35%1.44B | -3.94%723.98M | 10.83%3.35B | 1.14%2.58B | 3.22%1.64B |
| Selling expenses | 23.34%-7.13M | 28.03%-4.82M | 23.11%-3M | 35.83%-12.7M | 36.21%-9.3M | 43.39%-6.69M | 45.94%-3.9M | 44.38%-19.79M | 43.64%-14.58M | 31.87%-11.83M |
| Administrative expenses | -8.22%-300.6M | 1.29%-168.51M | 3.95%-85.58M | 4.78%-460.06M | 3.18%-277.76M | 6.54%-170.72M | 5.46%-89.1M | -8.89%-483.18M | 7.38%-286.9M | 5.49%-182.67M |
| Research and development expenses | -12.81%-25.98M | -7.56%-14.84M | 29.75%-4.38M | 1.63%-32.93M | -16.29%-23.03M | 0.80%-13.8M | -2.54%-6.23M | 27.97%-33.48M | 25.93%-19.8M | 23.84%-13.91M |
| Profit from asset sales | -91.91%40.74K | 42.26%-54.93K | ---- | -35.33%8.83M | -96.05%503.42K | -100.75%-95.13K | 316.77%26.96K | 87.11%13.65M | 163.40%12.75M | 163.89%12.75M |
| Revaluation surplus | 141.68%91.82M | 360.45%76.42M | 118.66%11.76M | -98.28%2.64M | -76.61%37.99M | -119.79%-29.34M | -11,580.55%-63.01M | 61.39%153.61M | 214.61%162.43M | 33.99%148.23M |
| -Changes in the fair value of other assets | 141.68%91.82M | 360.45%76.42M | 118.66%11.76M | -98.28%2.64M | -76.61%37.99M | -119.79%-29.34M | -11,580.55%-63.01M | 61.39%153.61M | 214.61%162.43M | 33.99%148.23M |
| Impairment and provision | 28.30%-96.86M | 30.77%-92.16M | -116.60%-5.98M | -151.27%-584.05M | -152.60%-135.09M | -134.40%-133.12M | -212.74%-2.76M | 6.03%-232.43M | -100.07%-53.48M | -137.22%-56.79M |
| -Other impairment is provision | 28.30%-96.86M | 30.77%-92.16M | -116.60%-5.98M | -151.27%-584.05M | -152.60%-135.09M | -134.40%-133.12M | -212.74%-2.76M | 6.03%-232.43M | -100.07%-53.48M | -137.22%-56.79M |
| Special items of operating profit | -15.31%684.36M | -27.70%424.29M | -31.28%255.26M | -32.38%1.05B | 20.80%808.07M | 55.51%586.84M | 73.33%371.46M | -0.97%1.55B | -53.97%668.96M | 8.03%377.37M |
| Operating profit | -4.87%2.52B | -0.69%1.64B | -10.53%822.64M | -33.39%2.83B | -12.36%2.65B | -12.89%1.65B | 7.89%919.47M | 9.81%4.25B | -17.11%3.02B | 6.33%1.9B |
| Financing cost | 24.77%-569.38M | 30.26%-389.91M | 29.20%-201.52M | 16.28%-1.04B | 20.78%-756.85M | 15.87%-559.05M | -9.51%-284.66M | 10.56%-1.24B | 14.91%-955.34M | 7.47%-664.49M |
| Adjustment items of earning before tax | -370.64%-11.46M | -44.42%2.76M | -94.38%162.19K | 62.48%-36.69M | 105.25%4.23M | 115.10%4.97M | 291.74%2.89M | -3,726.65%-97.78M | -1,182.97%-80.72M | -882.06%-32.89M |
| Earning before tax | 2.26%1.94B | 14.15%1.26B | -2.58%621.28M | -39.69%1.76B | -4.54%1.9B | -8.44%1.1B | 7.94%637.7M | 17.35%2.92B | -21.51%1.99B | 12.09%1.2B |
| Tax | 13.58%-342.17M | 9.61%-224.65M | 14.42%-106.99M | -1.97%-540.21M | 7.54%-395.93M | 8.03%-248.55M | -2.27%-125.03M | -0.09%-529.8M | 7.58%-428.22M | -41.15%-270.25M |
| After-tax profit from continuing operations | 6.44%1.6B | 21.09%1.03B | 0.31%514.28M | -48.94%1.22B | -3.72%1.5B | -8.56%851.18M | 9.43%512.67M | 22.02%2.39B | -24.63%1.56B | 5.77%930.82M |
| Earning after tax | 6.44%1.6B | 21.09%1.03B | 0.31%514.28M | -48.94%1.22B | -3.72%1.5B | -8.56%851.18M | 9.43%512.67M | 22.02%2.39B | -24.63%1.56B | 5.77%930.82M |
| Minority profit | 0.25%126.94M | -8.48%70.77M | -13.03%36.27M | 24.78%73.16M | 543.38%126.63M | 4,893.93%77.32M | 60.71%41.71M | 195.66%58.63M | -60.47%19.68M | -95.06%1.55M |
| Profit attributable to shareholders | 7.01%1.47B | 24.04%959.89M | 1.50%478.01M | -50.80%1.15B | -10.71%1.37B | -16.72%773.86M | 6.42%470.96M | 15.41%2.33B | -23.75%1.54B | 9.49%929.28M |
| Basic earnings per share | 1.59%0.575 | 22.44%0.382 | 4.10%0.203 | -55.09%0.441 | -11.84%0.566 | -18.75%0.312 | 7.14%0.195 | 17.04%0.982 | -25.44%0.642 | 10.66%0.384 |
| Diluted earnings per share | 1.59%0.575 | 22.44%0.382 | 4.10%0.203 | -55.09%0.441 | -11.84%0.566 | -18.75%0.312 | 7.14%0.195 | 17.04%0.982 | -25.44%0.642 | 10.66%0.384 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
| Auditor | -- | -- | -- | Deloitte Huayong Certified Public Accountants (Special General Partnership) | -- | -- | -- | Deloitte Huayong Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.